Skip to main content
. 2019 Feb 5;14(6):388–393. doi: 10.1159/000495186

Table 2.

Details of patients with recurrence-free survival (RFS) events

Patient number Trastuzumab Hormone receptor T stage Preoperative lymph node status RFS, months Detail of recurrence or cause of death
1 yes negative 2 SLNB positive 49 LR (ipsilateral chest wall)
2 yes negative 2 FNA positive 12 distant metastasis (brain)
3 yes negative 3 FNA positive 14 distant metastasis (brain)
4 yes negative 2 SLNB negative 28 distant metastasis (lung)
5 yes negative 2 FNA positive 38 secondary cancer (leukemia)
6 no negative 2 SLNB negative 91 CBC
7 no negative 1 FNA positive 128 CBC
8 no negative 2 SLNB negative 47 CBC
9 no negative 3 FNA positive 15 distant metastasis (liver)
10 no negative 2 SLNB negative 16 distant metastasis (lung)
11 no negative 2 FNA positive 43 IBTR + distant metastasis (contralateral axilla)
12 no negative 2 FNA positive 34 IBTR
13 no negative 2 SLNB negative 26 distant metastasis (liver and bone)
14 no negative 1 FNA positive 23 LR (ipsilateral chest wall) + RR (ipsilateral supraclavicular node)
15 no negative 2 SLN visualization failure 89 distant metastasis (lung)
16 no negative 1 SLNB negative 30 RR (ipsilateral axilla)
17 no negative 2 clinically suspicious 15 cause of death unknown
18 no negative 2 SLNB positive 44 secondary cancer (gastric)

SLNB, Sentinel lymph node biopsy; FNA, fine needle aspirate; LR, local recurrence; RR, regional recurrence; CBC, contralateral breast cancer; IBTR, ipsilateral breast tumor recurrence.